2型糖尿病多基因评分预测无糖尿病患者糖皮质激素所致高血糖风险
本研究回顾性分析546例未诊断糖尿病且接受泼尼松剂量≥10 mg的个体,发现2型糖尿病多基因评分每增加1个标准差与糖皮质激素所致高血糖相关(比值比1.4;P=0.038)。结论认为2型糖尿病遗传风险增高者发生糖皮质激素所致高血糖的风险更高,该发现为精准医疗中的风险分层提供了机制。
要点
- 在无糖尿病患者中,2型糖尿病多基因评分每增加1个标准差,糖皮质激素所致高血糖的比值比为1.4(P=0.038)。
- 546例接受糖皮质激素者中,210例发生高血糖,336例未发生。
- 2型糖尿病遗传风险增高与糖皮质激素所致高血糖风险升高相关。
核心结论
- 2型糖尿病遗传风险增高的个体发生糖皮质激素所致高血糖的风险更高。
- 该发现为精准医疗中的风险分层提供了机制。
研究设计与样本
- 回顾性分析未诊断糖尿病且接受泼尼松剂量≥10 mg的个体。
- 分析高血糖与2型糖尿病全局扩展多基因评分之间的关联,该评分通过两项已发表全基因组关联研究的荟萃分析构建。
主要发现
- 546例接受糖皮质激素的个体中,210例发生高血糖,336例未发生。
- 2型糖尿病多基因评分与糖皮质激素所致高血糖显著相关(比值比1.4/多基因评分每标准差;P=0.038)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether increased genetic risk of type 2 diabetes (T2D) is associated with the development of hyperglycemia after glucocorticoid treatment. RESEARCH DESIGN AND METHODS: We performed a retrospective analysis of individuals with no diagnosis of diabetes who received a glucocorticoid dose of ≥10 mg prednisone. We analyzed the association between hyperglycemia and a T2D global extended polygenic score, which was constructed through a meta-analysis of two published genome-wide association studies. RESULTS: Of 546 individuals who received glucocorticoids, 210 developed hyperglycemia and 336 did not. T2D polygenic score was significantly associated with glucocorticoid-induced hyperglycemia (odds ratio 1.4 per SD of polygenic score; P = 0.038). CONCLUSIONS: Individuals with increased genetic risk of T2D have a higher risk of glucocorticoid-induced hyperglycemia. This finding offers a mechanism for risk stratification as part of a precision approach to medical treatment.
引用
- Deutsch AJ, Schroeder PH, Mandla R, et al. Type 2 Diabetes Polygenic Score Predicts the Risk of Glucocorticoid-Induced Hyperglycemia in Patients Without Diabetes. Diabetes Care. 2023. PMID: 37353344. doi:10.2337/dc23-0353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。